fashion -WSS

fashion

author：comprehensive 2025-09-29 01:36:37 - browse：6425

A follow-up study of a first-of-its-kind cancer treatment may reflect systemic biases, the Food and Drug Administration said ahead of an advisory committee meeting Thursday to determine whether the drug should remain on the market.

The treatment, Lumakras, is designed to treat lung cancer caused by a specific genetic mutation to a protein called KRAS. It’s one of the most common genetic mutations in cancer, but repeated clinical trial failures had led researchers to deem it “undruggable” until a glimmer of hope came about a decade ago.

Lumakras received an accelerated, or conditional, approval in May 2021, making it the first KRAS drug on the market. Now, the drug’s manufacturer, Amgen, needs to prove it works.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： PBM executives asked to testify by House panel

explore

WSS

Medicare to cover more brain scans for Alzheimer’s patients

Welsh Carson private equity firm escapes from FTC antitrust case

The creative science of coining drug names

Listen: Wegovy in the brain & pivotal Alzheimer's data

Group opposing PBM reform sets lobbying record

Chemotherapy before breast cancer surgery might fuel metastasis

Wikipedia

fashion

explore

Hollywood unions extend contract negotiations for actors

Has Bernie Sanders reached the limit of his pharma bullying effort?

Cancer drug shortages should be causing more outrage

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Activists slam private health insurers over coverage restrictions

Custom gene therapy hints at new path for rare disease treatments

Virginia high school admissions case could be legal follow

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Continuity nursing helped my family in our darkest PICU moments

As billionaires fund anti

hotspot

Medicare to cover more brain scans for Alzheimer’s patients

Doctors find melanoma drugs effective against rare brain cancer

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

A public scorecard can help hold safety

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Cosmetics set for new safety regulation. Why the industry is on board

explore

hotspot

explore

leisure time